-
Bank of America Reiterates Buy and PT of $40 on NuVasive
Tuesday, July 26, 2011 - 6:24am | 61Bank of America reiterated its Buy rating on NuVasive (NASDAQ: NUVA). At the same time, the rating agency left its price target on the company's stock unchanged at $40. On Monday, NUVA lost 2.5% of its value to finish the day at $32.36. Its shares continued to slide in today's pre-market trading,...
-
JP Morgan Raises PT On NuVasive To $34
Tuesday, July 26, 2011 - 5:57am | 26JP Morgan has raised the price target on NuVasive (NASDAQ: NUVA) from $33 to $34 and maintains its Neutral rating.
-
BIOLASE Technology Jumps 14%
Monday, July 25, 2011 - 2:41pm | 122Shares of BIOLASE Technology (NASDAQ: BLTI) are jumping higher today; currently, shares are up by 14.37%, trading at $3.98. The stock has been meandering lower after a small gap higher, but has found an influx of buy volume within the past 30 minutes. BIOLASE Technology has been trading lower for...
-
Medtronic Resolute Drug-Eluting Stent Shows Superiority to Taxus® DES in Study of Patients with Coronary Artery Disease
Monday, July 25, 2011 - 2:31pm | 219The Resolute® drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT), showed superiority to Boston Scientific Corp.'s Taxus® DES on the primary endpoint of the RESOLUTE Japan clinical study: in-stent late lumen loss at eight months. The primary endpoint of RESOLUTE Japan compared 100 patients...
-
Boston Scientific Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter
Monday, July 25, 2011 - 1:49pm | 569Boston Scientific (NYSE: BSX) announces its next round of earnings this Thursday, July 28, 2011. Get prepared with Benzinga's ultimate preview for Boston Scientific's second quarter earnings. Earnings and Revenue: Analysts are predicting an EPS reading of 8 cents per share and revenues of $1....
-
Rodman & Renshaw Downgrades Insulet to Market Underperform
Monday, July 25, 2011 - 9:21am | 56Rodman & Renshaw downgraded its rating on Insulet (NASDAQ: PODD) to Market Underperform. At the moment, the rating agency has a price target on the company's stock unchanged at $18. On Friday, PODD closed the day at $22.51. Its shares lost 2.22% of their value in today's pre-market trading to...
-
Alphatec Spine Comments on Untitled Letter Related to PureGen Osteoprogenitor Cell Allograft
Monday, July 25, 2011 - 9:10am | 224Alphatec Holdings, Inc. (Nasdaq: ATEC) today commented on the United States Food and Drug Administration's (FDA) untitled letter dated June 23, 2011 that was sent to Parcell Laboratories, LLC regarding Alphatec Spine's PureGen Osteoprogenitor Cell Allograft product. In the letter, the FDA raised...
-
Hansen Medical Receives CE Mark for Its Magellan Robotic System for Peripheral Vascular Interventions
Monday, July 25, 2011 - 9:00am | 123Hansen Medical, Inc. (NASDAQ: HNSN) today announced that it has completed the European Union conformity assessment procedure and affixed a Conformité Européenne Mark on its Magellan™ Robotic System. The Magellan Robotic System is intended to facilitate navigation to anatomical targets in the...
-
China North East Petroleum Announces Court Decision to Deny Derivative Plaintiffs' Motion to Alter Judgment Regarding Dismissal of Lawsuit
Monday, July 25, 2011 - 8:33am | 159China North East Petroleum Holdings Limited (NYSE: NEP) today announced that on July 8, 2011, the United States District Court for the Southern District of New York issued a written opinion that denied a motion of Plaintiffs to re-open the consolidated shareholder derivative action against the...
-
Baxter Announces FDA Approval of Subcutaneous Route of Administration for GAMMAGARD LIQUID for Patients with Primary Immunodeficiency
Monday, July 25, 2011 - 8:31am | 88Baxter International Inc. (NYSE: BAX) announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency (PI). The approval of this new route of...
-
News Summary for July 25, 2011
Monday, July 25, 2011 - 7:51am | 610This is your Benzinga news summary and traders' outlook for Monday, July 25, 2011, covering headlines from overnight and Monday's pre-market session. Today in domestic pre-market trading, U.S. equity futures are trading lower after Congress failed to work out a deal to raise the debt ceiling over...
-
Benzinga's Top Upgrades
Monday, July 25, 2011 - 7:46am | 136Analysts at Credit Suisse upgraded Mindray Medical International Limited (NYSE: MR) from “neutral” to “outperform.” MR's shares closed at $26.95 on Friday. Mindray Medical's PEG ratio is 0.98. Analysts at BB&T Capital upgraded Brown Shoe Company Inc (NYSE: BWS) from “hold” to “buy.” BWS'...
-
J.P. Morgan Maintains Neutral on Thoratec
Monday, July 25, 2011 - 7:37am | 110J.P. Morgan is out with its report today on Thoratec (NASDAQ: THOR), maintaining Neutral. In a note to clients, J.P. Morgan writes, "Thoratec is the worldwide leader in ventricular assist devices, a market in which the company up until recently has held a near monopoly position. We believe that...
-
A Peek Into The Market Before The Trading Starts
Monday, July 25, 2011 - 7:23am | 390Pre-open movers US stock futures are lower this morning, as the nation's debt ceiling talks failed to progress. Futures for the Dow Jones Industrial Average dipped 95 points to 12,526.00 and S&P 500 index futures fell 9.80 points to 1,330.20. Nasdaq 100 futures dropped 14.75 points to 2,413.25...
-
Morgan Stanley Gives Color on Edwards Lifesciences After SAPIEN FDA Panel
Monday, July 25, 2011 - 6:46am | 139Morgan Stanley has published a report on Edwards Lifesciences (NYSE: EW). In the report, Morgan Stanley wrote, "The SAPIEN FDA panel was in line with the expectations we set forth heading into the meeting, but clearly the consensus debate narrowed rapidly and has pressured EW shares. In this note...